Commodore Capital’s Vaxcyte PCVX Stock Holding History

Commodore Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,650,000	Closed	-$62.3M	–	37
2025 Q1	$62.3M	Buy	1,650,000 +25,000	+2%	+$2M	4.59%	8
2024 Q4	$133M	Buy	1,625,000 +705,000	+77%	+$70M	9.75%	2
2024 Q3	$105M	Sell	920,000 -385,000	-30%	-$34.7M	6.57%	4
2024 Q2	$98.5M	Buy	1,305,000 +445,000	+52%	+$30.3M	6.73%	4
2024 Q1	$58.7M	Sell	860,000 -240,000	-22%	-$16.6M	3.93%	7
2023 Q4	$69.1M	Hold	1,100,000	–	–	6.04%	6
2023 Q3	$56.1M	Buy	1,100,000 +85,000	+8%	+$4.19M	6.55%	4
2023 Q2	$50.7M	Buy	1,015,000 +815,000	+408%	+$38.6M	5.7%	8
2023 Q1	$7.5M	Buy	200,000 +26,519	+15%	+$1.12M	1.14%	25
2022 Q4	$8.32M	Buy	+173,481	New	+$6.81M	1.25%	27

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital's PCVX Position: Q2 2025 in Review

Commodore Capital sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 1,650,000 shares — an estimated $62.3M sold.

Commodore Capital first reported a position in PCVX in Q4 2022 and held it in 10 quarters. The position peaked at $133M in Q4 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Commodore Capital reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Commodore Capital sold 1,650,000 Vaxcyte shares in Q2 2025, an estimated $62.3M.
Commodore Capital first reported a position in Vaxcyte in Q4 2022 and held it in 10 quarters.
Commodore Capital's Vaxcyte position peaked at $133M in Q4 2024.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.